<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436852</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL0621</org_study_id>
    <secondary_id>NCI-2009-00402</secondary_id>
    <secondary_id>NCI-07-C-0074</secondary_id>
    <secondary_id>CDR0000529858</secondary_id>
    <secondary_id>NCI-P6554</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <secondary_id>COG-ANBL0621</secondary_id>
    <nct_id>NCT00436852</nct_id>
  </id_info>
  <brief_title>ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment</brief_title>
  <official_title>A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well ABT-751 works in treating children with
      neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in
      chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the time to disease progression in children with refractory or relapsed
      neuroblastoma treated with ABT-751 vs historical controls.

      SECONDARY OBJECTIVES:

      I. Determine the objective response rate in patients with measurable disease treatment with
      this drug.

      II. Determine whether ABT-751 improves quality of life of these patients. III. Determine the
      toxicity of ABT-751. IV. Determine the pharmacokinetic profile of ABT-751 in these patients.

      OUTLINE:

      Patients receive oral ABT-751 once daily on days 1-7. Treatment repeats every 21 days for 52
      courses in the absence of disease progression or unacceptable toxicity.

      Blood is collected periodically during course 1 for pharmacokinetic studies. Quality of life
      is assessed at baseline and prior to each course of treatment.

      After completion of study treatment, patients are followed up for up to 5.1 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>From time to enrollment to death due to any cause, assessed up to 5.1 years</time_frame>
    <description>Median time to progression observed on ABT-751, along with 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year Progression-free Survival</measure>
    <time_frame>From the day of enrollment to the date of disease progression/recurrence , or the date of death (all causes of mortality) if disease progression/recurrence is not reached, assessed up to 1 yr. Pts were to be followed for 5 yrs after completion of therapy</time_frame>
    <description>PFS probabilities calculated using the Kaplan-Meier method, along 95% confidence intervals, separately for each stratum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Duration of protocol therapy</time_frame>
    <description>The proportion of patients who are responders will be tabulated, including a 95% confidence interval on the proportion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measured by PedsQL™ Generic Core Scale Version 4.0</measure>
    <time_frame>3 weeks</time_frame>
    <description>For each of the items within a Dimension, the QOL score will be reverse linearly transformed to a 0-100 percentage point scale (0=100, 1=75, 2=50, 3=25, 4=0), and the average of all items within a Dimension will be calculated. This results in 4 definitive scores at each timepoint. The average of all 23 items will be the Total Score at a given timepoint; and, 2) the repeated measures of performance status (Karnofsky score for patients &gt; 16 years of age and Lansky score for patients ≤ 16 years of age).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as Assessed by Common Terminology Criteria for Adverse Events Version 3.0</measure>
    <time_frame>yearsFrom enrollment until 30 days after the end of protocol therapy</time_frame>
    <description>Toxicity will be tabulated by grade (overall and by course).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Disseminated Neuroblastoma</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Measurable disease by CT or MRI scan (ABT-751 chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evaluable by I-MIBG scintigraphy (ABT-751)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-751</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Measurable disease by CT or MRI scan (ABT-751 chemotherapy)</arm_group_label>
    <arm_group_label>Evaluable by I-MIBG scintigraphy (ABT-751)</arm_group_label>
    <other_name>E7010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Measurable disease by CT or MRI scan (ABT-751 chemotherapy)</arm_group_label>
    <arm_group_label>Evaluable by I-MIBG scintigraphy (ABT-751)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed neuroblastoma meeting the following
             criteria:

               -  Refractory or relapsed disease

               -  No curative treatment option and no additional therapy proven to prolong survival
                  with an acceptable quality of life is available

               -  Evidence of disease progression (enlargement of existing measurable tumors or the
                  appearance of new tumors) during prior treatment OR biopsy-proven viable
                  neuroblastoma if stable disease but refractory to prior treatment

          -  Previously irradiated soft tissue or bony lesion must meet ≥ 1 of the following
             criteria:

               -  Viable neuroblastoma determined by biopsy ≥ 6 weeks after radiation therapy

               -  Growth in the lesion determined by CT scan or MRI

          -  Measurable or evaluable disease

               -  Measurable disease is defined as ≥ 20 mm in ≥ 1 dimension by MRI, CT scan, or
                  x-ray OR ≥ 10 mm in ≥ 1 dimension by spiral CT scan

               -  Evaluable disease is defined as iodine I 123 metaiodobenzylguanidine (^123I
                  MIBG)-positive lesion at ≥ 1 site

                    -  Must not have measurable disease by CT scan or MRI

               -  No elevated urinary catecholamines and/or bone marrow evidence of tumor, without
                  measurable or evaluable disease by imaging modalities (CT scan, MRI, or ^123I
                  MIBG)

          -  Karnofsky performance status (PS) 50-100% (&gt; 16 years of age) OR Lansky PS 50-100% (≤
             16 years of age)

          -  Life expectancy ≥ 8 weeks

          -  Hemoglobin ≥ 7.5 g/dL (transfusions allowed)

          -  Absolute neutrophil count &gt; 250/mm³

          -  Platelet count &gt; 25,000/mm³ (without platelet transfusion support for ≥ 7 days)

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT &lt; 5 times ULN

          -  Creatinine normal for age and gender as follows: OR creatinine clearance or
             radioisotope glomerular filtration rate ≥ 60 mL/min

               -  No greater than 0.4 mg/dL (≤ 5 months)

               -  No greater than 0.5 mg/dL (6 months-11 months)

               -  No greater than 0.6 mg/dL (1 year-23 months)

               -  No greater than 0.8 mg/dL (2 years-5 years)

               -  No greater than 1.0 mg/dL (6 years-9 years)

               -  No greater than 1.2 mg/dL (10 years-12 years)

               -  No greater than 1.4 mg/dL (13 years and over [female])

               -  No greater than 1.5 mg/dL (13 years to 15 years [male])

               -  No greater than 1.7 mg/dL (16 years and over [male])

          -  Shortening fraction ≥ 27% by echocardiogram

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-barrier contraception during and for 90
             days after completion of study treatment

          -  Seizure disorder allowed if controlled and receiving anticonvulsants

          -  Neurologic toxicity from prior therapy or tumor involvement ≤ grade 2

          -  No evidence of active graft-vs-host disease

          -  No allergy to sulfa-containing medications

          -  No known HIV positivity

          -  No clinically significant unrelated systemic illness (e.g., serious infection) that
             would limit study compliance

          -  Concurrent filgrastim (G-CSF) allowed if medically indicated

          -  Recovered from all prior therapy

          -  No prior ABT-751

          -  More than 2 weeks since prior myelosuppressive chemotherapy

          -  More than 7 days since prior anticancer biologic agents (e.g., retinoids)

          -  More than 4 weeks since prior palliative radiation therapy (small port) or therapeutic
             ^123I MIBG

          -  More than 6 weeks since prior substantial radiation therapy (&gt; 50% pelvis,
             craniospinal, or total-body radiation)

          -  More than 4 months since prior allogeneic stem cell transplantation (SCT) (2 months
             for autologous SCT) and recovered

               -  Infusion of autologous peripheral blood mononuclear cells without high-dose
                  chemotherapy or preparative regimen is not considered SCT

          -  More than 30 days since prior investigational drug therapy

          -  More than 30 days since prior immunotherapy (monoclonal antibody therapy or vaccine
             therapy)

          -  More than 1 week since prior growth factor treatment

          -  No other concurrent anticancer agents, including chemotherapy, immunomodulating
             agents, or biologic therapy (retinoids)

          -  No concurrent radiation therapy, including palliative radiation therapy

          -  No concurrent treatment for graft-vs-host disease

          -  No concurrent epoetin alfa, sargramostim (GM-CSF), or interleukin-11
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Fox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <results_first_submitted>November 19, 2013</results_first_submitted>
  <results_first_submitted_qc>January 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Disease Evaluable by I-MIBG Scintigraphy (ABT-751)</title>
          <description>Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.</description>
        </group>
        <group group_id="P2">
          <title>Measurable Disease by CT or MRI Scan (ABT-751)</title>
          <description>Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The protocol-specified definition of evaluability was applied. This was not an intention-to-treat analysis because patients who did not receive study drug were excluded (inevaluable).</population>
      <group_list>
        <group group_id="B1">
          <title>Disease Evaluable by I-MIBG Scintigraphy (ABT-751)</title>
          <description>Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.</description>
        </group>
        <group group_id="B2">
          <title>Measurable Disease by CT or MRI Scan (ABT-751)</title>
          <description>Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.46" lower_limit="6.23" upper_limit="12.91"/>
                    <measurement group_id="B2" value="7.55" lower_limit="5.91" upper_limit="12.43"/>
                    <measurement group_id="B3" value="8.00" lower_limit="6.07" upper_limit="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jamaica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors</title>
        <description>Median time to progression observed on ABT-751, along with 95% confidence intervals.</description>
        <time_frame>From time to enrollment to death due to any cause, assessed up to 5.1 years</time_frame>
        <population>The protocol-specified definition of evaluability was applied. This was not an intention-to-treat analysis because patients who did not receive study drug were excluded (inevaluable).</population>
        <group_list>
          <group group_id="O1">
            <title>Disease Evaluable by I-MIBG Scintigraphy (ABT-751)</title>
            <description>Patients who met study eligibility criteria and receive at least one dose of oral ABT-751 were evaluable for the efficacy analysis.</description>
          </group>
          <group group_id="O2">
            <title>Measurable Disease by CT or MRI Scan (ABT-751)</title>
            <description>Patients who met study eligibility criteria and receive at least one dose of oral ABT-751 were evaluable for the efficacy analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors</title>
          <description>Median time to progression observed on ABT-751, along with 95% confidence intervals.</description>
          <population>The protocol-specified definition of evaluability was applied. This was not an intention-to-treat analysis because patients who did not receive study drug were excluded (inevaluable).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="42" upper_limit="85"/>
                    <measurement group_id="O2" value="42" lower_limit="36" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>1-year Progression-free Survival</title>
        <description>PFS probabilities calculated using the Kaplan-Meier method, along 95% confidence intervals, separately for each stratum.</description>
        <time_frame>From the day of enrollment to the date of disease progression/recurrence , or the date of death (all causes of mortality) if disease progression/recurrence is not reached, assessed up to 1 yr. Pts were to be followed for 5 yrs after completion of therapy</time_frame>
        <population>The protocol-specified definition of evaluability was applied. This was not an intention-to-treat analysis because patients who did not receive study drug were excluded (inevaluable).</population>
        <group_list>
          <group group_id="O1">
            <title>Disease Evaluable by I-MIBG Scintigraphy (ABT-751)</title>
            <description>Patients who met study eligibility criteria and receive at least one dose of oral ABT-751 were evaluable for the efficacy analysis.</description>
          </group>
          <group group_id="O2">
            <title>Measurable Disease by CT or MRI Scan (ABT-751)</title>
            <description>Patients who met study eligibility criteria and receive at least one dose of oral ABT-751 were evaluable for the efficacy analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Progression-free Survival</title>
          <description>PFS probabilities calculated using the Kaplan-Meier method, along 95% confidence intervals, separately for each stratum.</description>
          <population>The protocol-specified definition of evaluability was applied. This was not an intention-to-treat analysis because patients who did not receive study drug were excluded (inevaluable).</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="7" upper_limit="31"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>The proportion of patients who are responders will be tabulated, including a 95% confidence interval on the proportion.</description>
        <time_frame>Duration of protocol therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measured by PedsQL™ Generic Core Scale Version 4.0</title>
        <description>For each of the items within a Dimension, the QOL score will be reverse linearly transformed to a 0-100 percentage point scale (0=100, 1=75, 2=50, 3=25, 4=0), and the average of all items within a Dimension will be calculated. This results in 4 definitive scores at each timepoint. The average of all 23 items will be the Total Score at a given timepoint; and, 2) the repeated measures of performance status (Karnofsky score for patients &gt; 16 years of age and Lansky score for patients ≤ 16 years of age).</description>
        <time_frame>3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity as Assessed by Common Terminology Criteria for Adverse Events Version 3.0</title>
        <description>Toxicity will be tabulated by grade (overall and by course).</description>
        <time_frame>yearsFrom enrollment until 30 days after the end of protocol therapy</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Disease Evaluable by I-MIBG Scintigraphy (ABT-751)</title>
          <description>Patients who met study eligibility criteria and receive at least one dose of oral ABT-751 were evaluable for the efficacy analysis.</description>
        </group>
        <group group_id="E2">
          <title>Measurable Disease by CT or MRI Scan (ABT-751)</title>
          <description>Patients who met study eligibility criteria and receive at least one dose of oral ABT-751 were evaluable for the efficacy analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia (fever, unk. origin,w/o infection,ANC&lt;1x10e9, fever&gt;=38.5C)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Obstruction, GI - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term - Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gait/walking: Extremity-lower (gait/walking)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (clinical or microbiological Dx) w/ Gr 3-4 neutrophils, ANC&lt;1.0x10e9 - Blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection (clinical or microbiological Dx) w/ Gr 3-4 neutrophils, ANC&lt;1.0x10e9 - Paranasal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Blood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Bone (osteomyelitis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Catheter-related</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Sinus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC - Middle ear (otitis media)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoglycemia: Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypokalemia: Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyponatremia: Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Neuralgia/peripheral nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood alteration - Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>&quot; Bronchospasm, wheezing&quot;</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Stomach</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>&quot; Fatigue (asthenia, lethargy, malaise)&quot;</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot; Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)&quot;</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils - Sinus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>&quot;ALT, SGPT (serum glutamic pyruvic transaminase)&quot;</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;AST: AST, SGOT(serum glutamic oxaloacetic transaminase)&quot;</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot; Cholesterol: Cholesterol, serum-high (hypercholestremia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>GGT: GGT (gamma-Glutamyl transpeptidase)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Albumin, serum-low (hypoalbuminemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Bicarbonate, serum-low&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypercalcemia: Calcium, serum-high (hypercalcemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hyperglycemia: Glucose, serum-high (hyperglycemia)&quot;</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypermagnesemia: Magnesium, serum-high (hypermagnesemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypertriglyceridemia: Triglyceride, serum-high (hypertriglyceridemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypocalcemia: Calcium, serum-low (hypocalcemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypoglycemia: Glucose, serum-low (hypoglycemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypokalemia: Potassium, serum-low (hypokalemia)&quot;</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypomagnesemia: Magnesium, serum-low (hypomagnesemia)&quot;</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hyponatremia: Sodium, serum-low (hyponatremia)&quot;</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot;Hypophosphatemia: Phosphate, serum-low (hypophosphatemia)&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Extremity-limb</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Head/headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood alteration - Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>&quot; Hemorrhage, pulmonary/upper respiratory - Nose&quot;</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain - Throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

